FRAXA Contributes $10,000 to NIH grant to Seaside Therapeutics

Randall Carpenter, MD, at Massachusetts Institute of Technology, FRAXA research grantRandy Carpenter, MD
Principal Investigator

with Mark Bear, PhD, MIT
Co-Investigator (2007)

 

Clinical development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism

Seaside Therapeutics received a major grant from the NIH, with additional funding from FRAXA and Cure Autism Now (CAN) to develop STX107, a selective mGluR5 antagonist, as a treatment for Fragile X.

Unfortunately Seaside has since discontinued development of STX107.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.